Vol 6, Supplement 1 (December 21, 2017): Translational Lung Cancer Research

Original Article

Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC)

Rezarta Frakulli, Fabrizio Salvi, Damiano Balestrini, Marcella Palombarini, Ilir Akshija, Silvia Cammelli, Alessio Giuseppe Morganti, Maurizio Zompatori, Giovanni Frezza

PDF Pages: S1-S7 Full Text (3080) Open Access

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta- analysis

Yang-Bo Hu, Qun Zhang, Hui-Juan Li, Jean Maire Michot, Hong-Bing Liu, Ping Zhan, Tang-Feng Lv, Yong Song, written on behalf of the AME Academic Lung Cancer Cooperation Group

PDF Pages: S8-S20 Full Text (4512) Open Access

Review Article

Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis

José Luís González-Larriba, Martín Lázaro-Quintela, Manuel Cobo, Manuel Dómine, Margarita Majem, Rosario García-Campelo

PDF Pages: S21-S34 Full Text (3076) Open Access

Editorial

Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer

Ignacio Gil-Bazo

PDF Pages: S35-S38 Full Text (1477) Open Access

Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study

Aaron Lisberg, Edward B. Garon

PDF Pages: S39-S40 Full Text (1514) Open Access

Avelumab: another active immune checkpoint inhibitor in nonsmall cell lung cancer

Hao Xie, Alex A. Adjei

PDF Pages: S41-S43 Full Text (1715) Open Access

Young low and middle-income country (LMIC) smokers— implications for global tobacco control

Emily Stone, Matthew Peters

PDF Pages: S44-S46 Full Text (2429) Open Access

Perspectives in small cell lung cancer: is something moving?

Lucio Crinò, Angelo Delmonte

PDF Pages: S47-S50 Full Text (1538) Open Access

Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them

Marius Ilie, Paul Hofman

PDF Pages: S51-S54 Full Text (1635) Open Access

The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated nonsmall cell lung cancer

Anthony M. Brade

PDF Pages: S55-S57 Full Text (1733) Open Access

Raising the bar: the future of EGFR inhibition in non-small lung cancer

Amanda J. Redig

PDF Pages: S58-S61 Full Text (1956) Open Access

Osimertinib as first-line treatment of EGFR mutant advanced nonsmall- cell lung cancer

Chong-Kin Liam

PDF Pages: S62-S66 Full Text (4798) Open Access

Small-cell lung cancer in the era of immunotherapy

Margarita Majem, Charles M. Rudin

PDF Pages: S67-S70 Full Text (2345) Open Access

Can we omit radiotherapy in case of brain metastases for patients with mutant EGFR lung adenocarcinoma?

Paul Jules Van Houtte, Daniel Devriendt

PDF Pages: S71-S73 Full Text (1258) Open Access

The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?

Giancarlo Troncone, Cesare Gridelli

PDF Pages: S74-S77 Full Text (2309) Open Access

Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

Alejandro Navarro, Enriqueta Felip

PDF Pages: S78-S83 Full Text (3215) Open Access

KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?

Jose M. Pacheco, D. Ross Camidge

PDF Pages: S84-S87 Full Text (2971) Open Access

Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?

Wolfram C. M. Dempke, Klaus Fenchel

PDF Pages: S88-S91 Full Text (1522) Open Access

Meet the Professor

Dr. Tetsuya Mitsudomi: next generation sequencing may become the focus of the future study in the field of lung cancer

Gin Li, Macy Liu

PDF Pages: S92-S93 Full Text (Video) (1776) Open Access

Dr. Peter Ujhazy: research for the greater good

Bella Poon, Macy Liu

PDF Pages: S94-S96 Full Text (Video) (1311) Open Access

Dr. Mari Mino-Kenudson: challenges and future developments in the field of biopsy

Gin Li, Macy Liu

PDF Pages: S97-S98 Full Text (Video) (1281) Open Access

Dr. Viola Zhu: is ethnicity a prognostic factor in lung cancer?

Macy Liu

PDF Pages: S99-S100 Full Text (1089) Open Access

Dr. Erik Thunnissen: how to appropriately optimize the handling of surgically resected specimens

Bella Poon, Chao-Xiu He

PDF Pages: S101-S102 Full Text (Video) (1179) Open Access

Professor Jacek Jassem: we can never emphasize too much on tobacco-control

Vivian Kong, Chao-Xiu(Melanie) He

PDF Pages: S103-S105 Full Text (Video) (1566) Open Access

Presidential remarks: WCLC 2017, a successful conference with record-breaking attendance and high scientific quality

Chao-Xiu(Melanie) He

PDF Pages: S106-S107 Full Text (Video) (1496) Open Access

Professor Heather A. Wakelee: facing new progress in lung cancer research, keep in mind how do we best help patients

Kaiping Zhang

PDF Pages: S108-S110 Full Text (1338) Open Access

Dr. Giannis Mountzios: immunotherapy, an “earthquake” in the treatment of advanced lung cancer

Nikki Ling

PDF Pages: S111-S112 Full Text (1249) Open Access

Prof. Silvia Novello: our job—a choice of life that has to be renewed every day

Nikki Ling

PDF Pages: S113-S115 Full Text (1700) Open Access

Disclosure:

The supplement was published without any sponsorship or funding.